Clinical Guides
Hepatitis C: Diagnosis, Curative Treatment and Follow-up
Hepatitis C is a blood-borne infection diagnosed in two steps and usually curable with direct-acting antivirals when confirmed infection is linked to appropriate care.
MedNext Academy | 12 min read
Hepatitis C: Diagnosis, Curative Treatment and Follow-up
Hepatitis C is a blood-borne infection diagnosed in two steps and usually curable with direct-acting antivirals when confirmed infection is linked to appropriate care.
Summary
Hepatitis C virus (HCV) infection ranges from acute, often unnoticed illness to chronic hepatitis, cirrhosis and hepatocellular carcinoma. Most transmission occurs through exposure to infected blood: unsafe medical injections or procedures, inadequately screened blood, and shared injecting equipment are important routes. Sexual transmission and mother-to-child transmission are less common but can occur when blood exposure is involved. HCV is not transmitted by food, water, breast milk, hugging, kissing or sharing meals.
Acute infection is commonly asymptomatic. When symptoms occur, they are non-specific: fatigue, nausea, anorexia, abdominal pain, dark urine, pale stool, joint pain and jaundice. Around 30% of infected people spontaneously clear infection within six months, so a positive antibody test does not by itself prove current viraemia. Diagnosis requires an anti-HCV antibody test followed by a nucleic-acid test for HCV RNA to establish current infection and treatment need.
Modern direct-acting antivirals (DAAs) cure more than 95% of people when used correctly, but cure does not protect against reinfection and does not reverse established cirrhosis immediately. This guide is clinically focused educational material, not a prescription. Regimen selection, duration, interaction review and post-cure surveillance require the current Indian programme pathway and patient-specific assessment. [WHO HCV Fact Sheet, Testing and diagnosis; Treatment]
How Common Is It?
WHO estimates that 47 million people had chronic HCV infection globally in 2024 and approximately 0.9 million new infections occurred each year. It estimated about 239,000 HCV-related deaths in 2024, predominantly from cirrhosis and primary liver cancer. These figures carry uncertainty intervals and should not be converted into a prediction for an individual patient, state or clinic. The clinical burden is partly hidden because people may remain asymptomatic for decades before cirrhosis complications appear.
WHO states that about 30% of people clear acute infection spontaneously within six months, while 70% develop chronic infection. Among people with chronic infection, cirrhosis risk is estimated at 15% to 30% over 20 years. Progression varies with alcohol, age at infection, HIV or HBV coinfection, diabetes, obesity, ongoing hepatic injury and access to diagnosis and curative treatment. A normal alanine aminotransferase result does not exclude chronic HCV or fibrosis.
India has diverse epidemiology and access to testing. The appropriate public-service reference is the National Viral Hepatitis Control Programme, which set goals for high-risk-group screening, rapid testing, viral-load capacity and treatment linkage. Its rollout targets do not prove current coverage at each primary centre, district hospital or state. Avoid unsupported claims that HCV is concentrated only in one group; testing should follow exposures, clinical indication, local epidemiology and the current programme policy. [WHO HCV Fact Sheet, Key facts and Overview; NVHCP Operational Guidelines, Diagnosis targets]
Risk Factors
Ask sensitively about blood exposure without assuming injecting drug use or unsafe behaviour. Relevant exposures include injection-drug equipment sharing, transfusion or blood products in periods or settings with uncertain screening, dialysis, unsafe injections, inadequately sterilised medical or dental equipment, occupational sharps injury, tattooing or piercing with uncertain infection control, and incarceration or other closed settings. Ask about HIV, HBV, tuberculosis care, migration from a higher-burden area and previous HCV testing or treatment.
Sexual transmission is less efficient than parenteral transmission, but risk rises when sex involves blood exposure, trauma, multiple partners or certain networks. Mother-to-child transmission can occur but is less common. Do not promise a risk-free route based on a brief history; use the history to offer appropriate testing and prevention counselling. A cured infection confers no vaccine-like immunity, so reinfection is possible with later exposure.
Before DAA treatment, identify factors affecting prognosis and medicine safety: cirrhosis or decompensation, renal disease, pregnancy, HBV coinfection, HIV therapy, transplant history, prior DAA exposure, alcohol, metabolic disease and all prescription, over-the-counter, herbal and recreational substances. WHO recommends testing people at increased risk in all settings and, where HCV antibody seroprevalence exceeds 2%, general population testing of adolescents and adults. That prevalence threshold is WHO guidance, not a statement that every Indian locality meets it. [WHO HCV Fact Sheet, Transmission and Testing; WHO Consolidated Handbook 2026, testing and prevention chapters]
Diagnosis
History
Document symptoms, prior exposures, previous antibody or RNA results, prior DAA treatment, alcohol, medicine and supplement use, pregnancy, comorbidities and symptoms of decompensation. Ask about jaundice, fatigue, pruritus, dark urine, abdominal distension, confusion, gastrointestinal bleeding, reduced urine output and weight loss. Identify risk of reinfection and whether partners, household members or injecting contacts need prevention support. Clarify that contacts need testing based on credible blood exposure, not casual contact.
Examination
Examine for jaundice, hepatomegaly, splenomegaly, ascites, oedema, bruising, muscle wasting, encephalopathy and stigmata of chronic liver disease. Check observations, hydration, mental state, blood pressure and metabolic factors. A normal examination is common in chronic infection and does not remove the need for staging. Ascites, asterixis, haematemesis, melaena, shock, fever with ascites or marked jaundice indicate urgent complications rather than a routine DAA clinic visit.
Investigations
Use a quality-assured anti-HCV antibody assay as the screening step. A positive antibody result must be followed by HCV RNA nucleic-acid testing to confirm current infection because antibody persists after spontaneous clearance or cure. Once current infection is confirmed, stage liver disease using validated non-invasive tests and/or elastography, with biopsy only selectively. Obtain liver tests, full blood count, INR, renal function, pregnancy test where applicable, and HIV/HBV testing. Genotype may be unnecessary for simplified pan-genotypic treatment pathways but can still matter in selected cases; follow current local protocol. [WHO HCV Fact Sheet, Testing and diagnosis; WHO Consolidated Handbook 2026, testing chapter]
Differential Diagnosis
Acute jaundice or raised aminotransferases can result from hepatitis A, B or E, drug-induced liver injury, alcohol-associated hepatitis, autoimmune hepatitis, biliary obstruction, ischaemia, sepsis, metabolic liver disease or other systemic infections. A positive HCV antibody may reflect resolved infection rather than the cause of current illness; RNA confirmation is essential. Acute paracetamol toxicity, severe cholangitis and acute liver failure require emergency pathways and should not wait for outpatient hepatitis staging.
In established HCV, abnormal liver tests or symptoms may arise from alcohol, metabolic dysfunction-associated steatotic liver disease, HBV/HIV coinfection, medicines, portal-vein problems, biliary disease or hepatocellular carcinoma. DAA treatment cures current HCV infection in most people, but it does not prove that all liver injury is HCV-mediated. Persistently abnormal tests after sustained virological response require a fresh differential rather than automatic retreatment.
Differentiate compensated cirrhosis from decompensated disease. Ascites, variceal bleed, encephalopathy and jaundice change treatment setting, monitoring and referral urgency. In India, hepatitis E is a particularly relevant cause of acute jaundice, especially in pregnancy; tuberculosis treatment and other drugs can cause liver injury. Test and assess the patient rather than applying an epidemiological label. [WHO HCV Fact Sheet, diagnosis and liver damage assessment; WHO Consolidated Handbook 2026, care and monitoring chapters]
Management
Link everyone with confirmed current HCV infection to treatment assessment. WHO recommends pan-genotypic DAAs for adults, adolescents and children down to age three with chronic infection. Cure rates exceed 95% when an appropriate regimen is completed, but the person must be evaluated for cirrhosis, prior treatment, HBV/HIV coinfection, pregnancy, renal impairment and drug interactions first. Simplified models permit trained non-specialist delivery for suitable patients, but complex disease still needs specialist input.
Address the whole care pathway: counsel that treatment is curative rather than preventive; reduce blood-borne risk; support sterile injecting equipment and opioid-substitution services where needed; avoid alcohol; manage diabetes and obesity; and check vaccination or susceptibility to hepatitis A and B according to local care. Never exclude a person who injects drugs from treatment solely because of ongoing use; reinfection prevention and harm reduction should be integrated. Test of cure uses HCV RNA after the recommended post-treatment interval, not antibody, which remains positive.
Cirrhosis needs risk-based surveillance and complication care even after cure. A sustained virological response reduces but does not abolish hepatocellular carcinoma risk in those with advanced fibrosis or cirrhosis. The exact surveillance test and interval should follow a current local hepatology protocol. India's NVHCP supports diagnosis and treatment expansion, but decentralised availability, viral-load turnaround, specialist backup and free medicine supply differ by state and facility. [WHO HCV Fact Sheet, Treatment and Service delivery; WHO Consolidated Handbook 2026, treatment and monitoring chapters]
Prescribing Information
DAAs are highly effective but are not one-size-fits-all tablets. WHO notes that pan-genotypic oral regimens can cure most people and that many treatment courses last 12 to 24 weeks depending on cirrhosis. The currently authorised Indian regimen, duration and supply pathway must be confirmed from NVHCP or institutional guidance; do not prescribe from a foreign product list. Verify current infection with HCV RNA, assess compensated versus decompensated cirrhosis, calculate renal function, review prior DAA exposure and reconcile every medicine.
Drug interactions are a major preventable source of failure or toxicity. Acid-suppressants, anticonvulsants, antimicrobials, antiarrhythmics, statins, antiretrovirals, transplant medicines and herbal products can be relevant depending on the DAA regimen. Use an up-to-date interaction resource and pharmacist or specialist input rather than relying on memory. Pregnancy requires expert discussion because regimen-specific evidence and regulatory advice may be limited; contraception or timing decisions must be individualised.
Screen for HBV before DAA therapy and plan monitoring or prophylaxis according to current guidance, because HBV reactivation can occur during or after HCV DAA treatment. Do not use interferon-era assumptions to deny treatment, and do not repeat or combine DAAs after apparent failure without viral and adherence review. At cure assessment, use RNA, not anti-HCV antibody. Check locally available formulations, CDSCO information, renal and hepatic dosing cautions and the programme stock before dispensing. [WHO Consolidated Handbook 2026, treatment and HBV/HCV integration chapters; WHO HCV Fact Sheet, Treatment]
When to Refer
Refer urgently to emergency or hepatology-capable care for confusion, asterixis, gastrointestinal bleeding, shock, ascites with fever, severe jaundice, acute kidney injury, severe vomiting, suspected sepsis, rapidly worsening abdominal distension, hepatocellular carcinoma symptoms or decompensated cirrhosis. These presentations need stabilisation and complication management; they are not routine treatment-initiation visits. Arrange urgent obstetric and medical assessment for pregnant people with significant liver dysfunction or acute jaundice.
Refer promptly for DAA regimen selection when there is cirrhosis, prior DAA failure, transplant, dialysis or severe renal disease, HIV or HBV coinfection, interacting medicines that cannot safely be modified, suspected hepatocellular carcinoma, child or adolescent treatment, or uncertainty about current viraemia. Refer if fibrosis assessment, ultrasound or blood tests suggest advanced disease. People with simple confirmed infection may be treated in decentralised services only when those services can safely verify RNA, assess liver disease, supply medicines and arrange cure testing.
NVHCP operational guidance proposes treatment centres at state and district level and viral-load capability through designated diagnostics. This is a system design, not a guarantee of same-day access. Confirm whether the referral destination can perform RNA testing, elastography/ultrasound, manage decompensation, review drug interactions and support follow-up. Record the result, contact method, appointment and return precautions. [NVHCP Operational Guidelines, Diagnosis and Treatment targets; WHO HCV Fact Sheet, Service delivery]
Red Flags
Recognise liver decompensation: haematemesis, melaena, new confusion or sleep reversal, asterixis, ascites, fever with ascites, rapidly increasing oedema, severe jaundice, hypotension, reduced urine output and profound weakness require immediate assessment. In a person with acute hepatitis symptoms, encephalopathy or coagulopathy suggests acute liver failure. Do not reassure someone with an HCV antibody result alone when they have emergency symptoms.
Cancer warning features include progressive weight loss, persistent right-upper-quadrant pain, palpable mass, worsening ascites or jaundice in a person with chronic liver disease. These require imaging and hepatology/oncology pathways. A normal ultrasound at an earlier time point does not rule out new disease. Post-cure patients with advanced fibrosis or cirrhosis still need their risk-based surveillance plan.
Before DAA therapy, red flags for specialist review include decompensated cirrhosis, uncertain diagnosis, HBV positivity, complex HIV therapy, pregnancy, transplant medicines, severe renal disease, previous treatment failure and major interaction risk. During therapy, promptly assess marked rash, breathing symptoms, persistent vomiting, jaundice, confusion or a new bleeding event. Self-stopping medication after a mild transient symptom can reduce cure likelihood; discuss concerns urgently with the dispensing service. [WHO Consolidated Handbook 2026, treatment, monitoring and service delivery chapters]
Indian Clinical Context
The National Viral Hepatitis Control Programme is the Indian public-health framework for hepatitis C prevention, testing, diagnosis and treatment. Its operational guideline envisages rapid diagnostic testing at multiple levels, viral-load capacity at designated district diagnostics, model treatment centres in each state or union territory and district treatment centres. That framework makes a practical referral map, but it does not ensure uniform RNA availability, appointment timing, pan-genotypic DAA stock, elastography, ultrasound or specialist services across India.
At primary contact, avoid stigma, confirm the two-test pathway and address immediate danger signs. Ensure the antibody-positive patient is not lost before RNA confirmation, and ensure RNA-positive patients are not lost before staging and treatment. A written referral should include antibody and RNA results, liver/renal tests, pregnancy status, cirrhosis clues, HBV/HIV status, complete medicines and contact details. When transport, wage loss or digital access are barriers, use the closest verified NVHCP route and simplify appointments where local services permit.
India-specific counselling should correct myths about casual spread and reinfection, avoid unregulated herbal treatment, and integrate harm reduction rather than moralising. WHO recommendations and international cure figures are evidence support, not a promise of free treatment or a substitute for local eligibility and procurement rules. Treatment and surveillance decisions should be revisited as NVHCP technical guidance changes. [NVHCP Operational Guidelines, prevention, diagnosis and treatment plans; WHO Consolidated Handbook 2026, adaptable service delivery]
NMC Competency Mapping
The NMC Competency Based Medical Education Curriculum 2024 supports an integrated approach to viral hepatitis across medicine, microbiology, pharmacology, community medicine and ethics. Learners should use their institution's current competency table for exact coding rather than invent a code from a secondary summary. The educational tasks are clinically concrete: recognise a blood-borne risk history without stigma, differentiate screening from confirmation, identify decompensation, understand cure versus immunity and organise safe referral.
A student should be able to explain why anti-HCV antibody and HCV RNA answer different questions; take a focused exposure, alcohol and medicine history; examine for chronic liver disease; request baseline tests with supervision; and identify when ascites, encephalopathy, bleeding or jaundice require emergency care. They should counsel that ordinary contact does not transmit HCV and that treatment can cure active infection but reinfection is possible.
Students are not authorised to select a DAA regimen, alter antiretrovirals, manage liver failure, discontinue immunosuppression or declare cure on the basis of antibody. Good assessment includes communication with a person who injects drugs, interpretation of an antibody-positive/RNA-negative result, and a care-plan handover for compensated versus decompensated cirrhosis. Credit safety-netting, consent, confidentiality and linkage to real services alongside factual recall. [NMC CBME 2024, curriculum framework and assessment principles]
Key Exam Pearls for NEET PG
HCV is chiefly blood-borne. Acute infection is often silent; chronic infection may progress to cirrhosis and hepatocellular carcinoma. Anti-HCV antibody shows exposure, not necessarily current infection. Confirm current infection with HCV RNA because spontaneous clearance and cured infection remain antibody positive. A positive antibody test should trigger linkage to RNA testing, not a declaration of chronic disease.
About 30% spontaneously clear acute infection; the remainder commonly become chronic. Pan-genotypic DAAs cure more than 95% when appropriately selected and completed. Cure does not protect against reinfection. Before treatment, stage fibrosis/cirrhosis, review renal function and medicines, check HBV/HIV status, identify pregnancy and distinguish compensated from decompensated disease. HBV reactivation is a safety consideration during DAA care.
Haematemesis, melaena, ascites, encephalopathy, fever with ascites, jaundice with deterioration and acute kidney injury are urgent red flags. HCV is not transmitted by food, water, breast milk or ordinary hugging and meal sharing. For an India-oriented answer, mention NVHCP linkage but do not invent a universal local regimen, price or waiting time. The best structured answer is two-step diagnosis, fibrosis staging, DAA treatment, cure testing with RNA, reinfection prevention and surveillance where advanced liver disease persists. [WHO HCV Fact Sheet, Transmission, Testing and Treatment; NVHCP Operational Guidelines, diagnosis and treatment sections]
Frequently Asked Questions
If anti-HCV antibody is positive, does that prove someone currently has hepatitis C?
No. Antibody means previous exposure and remains positive after spontaneous clearance or successful treatment. A nucleic-acid test for HCV RNA is required to show current viraemia and determine treatment need. A person with a positive antibody and negative RNA should receive interpretation and prevention counselling, not unnecessary DAA treatment.
Can hepatitis C be cured, and can it return after successful treatment?
Appropriate direct-acting antiviral treatment cures more than 95% of confirmed infections. Cure is checked with an HCV RNA test at the recommended post-treatment time. Antibody remains positive and does not measure cure. A new blood-borne exposure can cause reinfection, so harm reduction, safe injections and contact counselling remain important after cure.
Should everyone with hepatitis C be treated only by a liver specialist?
Not necessarily. WHO supports trained non-specialist, decentralised delivery for uncomplicated confirmed infection when safe testing, staging, medicine supply and follow-up exist. Cirrhosis, decompensation, transplant, dialysis, pregnancy, complex interactions, HBV/HIV coinfection and previous DAA failure need specialist-capable assessment. Local Indian service availability determines the safest route.
Can hepatitis C spread by sharing food, water bottles or hugging family members?
No. HCV is transmitted primarily through infected blood. It is not spread through food, water, breastfeeding, hugging, kissing or ordinary household contact. Do not share injecting equipment or personal items that may be blood-contaminated, such as razors or toothbrushes. Families should focus on testing and treatment access rather than isolating the affected person.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic